• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌腹水的蛋白质组资源:综合蛋白质组学和生物信息学分析以鉴定潜在生物标志物

A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers.

作者信息

Gortzak-Uzan Limor, Ignatchenko Alex, Evangelou Andreas I, Agochiya Mahima, Brown Kevin A, St Onge Peter, Kireeva Inga, Schmitt-Ulms Gerold, Brown Theodore J, Murphy Joan, Rosen Barry, Shaw Patricia, Jurisica Igor, Kislinger Thomas

机构信息

Ontario Cancer Institute, Division of Cancer Genomics and Proteomics, Canada.

出版信息

J Proteome Res. 2008 Jan;7(1):339-51. doi: 10.1021/pr0703223. Epub 2007 Dec 13.

DOI:10.1021/pr0703223
PMID:18076136
Abstract

Epithelial ovarian cancer is the most lethal gynecological malignancy, and disease-specific biomarkers are urgently needed to improve diagnosis, prognosis, and to predict and monitor treatment efficiency. We present an in-depth proteomic analysis of selected biochemical fractions of human ovarian cancer ascites, resulting in the stringent and confident identification of over 2500 proteins. Rigorous filter schemes were applied to objectively minimize the number of false-positive identifications, and we only report proteins with substantial peptide evidence. Integrated computational analysis of the ascites proteome combined with several recently published proteomic data sets of human plasma, urine, 59 ovarian cancer related microarray data sets, and protein-protein interactions from the Interologous Interaction Database I (2)D ( http://ophid.utoronto.ca/i2d) resulted in a short-list of 80 putative biomarkers. The presented proteomics analysis provides a significant resource for ovarian cancer research, and a framework for biomarker discovery.

摘要

上皮性卵巢癌是最致命的妇科恶性肿瘤,迫切需要疾病特异性生物标志物来改善诊断、预后,并预测和监测治疗效果。我们对人卵巢癌腹水的选定生化组分进行了深入的蛋白质组学分析,严格且可靠地鉴定出了2500多种蛋白质。应用了严格的筛选方案以客观地减少假阳性鉴定的数量,并且我们只报告有大量肽段证据的蛋白质。对腹水蛋白质组进行综合计算分析,并结合最近发表的几个人血浆、尿液蛋白质组数据集、59个卵巢癌相关微阵列数据集以及来自同源相互作用数据库I(2)D(http://ophid.utoronto.ca/i2d)的蛋白质-蛋白质相互作用,得出了一份包含80种假定生物标志物的简短清单。所呈现的蛋白质组学分析为卵巢癌研究提供了重要资源,以及生物标志物发现的框架。

相似文献

1
A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers.卵巢癌腹水的蛋白质组资源:综合蛋白质组学和生物信息学分析以鉴定潜在生物标志物
J Proteome Res. 2008 Jan;7(1):339-51. doi: 10.1021/pr0703223. Epub 2007 Dec 13.
2
In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry.卵巢癌腹水的深度蛋白质组学研究:组合型 shotgun 蛋白质组学和选择反应监测质谱法。
J Proteome Res. 2011 May 6;10(5):2286-99. doi: 10.1021/pr1011087. Epub 2011 Apr 14.
3
PCHM: A bioinformatic resource for high-throughput human mitochondrial proteome searching and comparison.PCHM:用于高通量人类线粒体蛋白质组搜索和比较的生物信息资源。
Comput Biol Med. 2009 Aug;39(8):689-96. doi: 10.1016/j.compbiomed.2009.05.006. Epub 2009 Jun 21.
4
Classifications of ovarian cancer tissues by proteomic patterns.通过蛋白质组学模式对卵巢癌组织进行分类。
Proteomics. 2006 Nov;6(21):5846-56. doi: 10.1002/pmic.200600165.
5
Application of proteomics in ovarian cancer: which sample should be used?蛋白质组学在卵巢癌中的应用:应使用哪种样本?
Gynecol Oncol. 2009 Dec;115(3):497-503. doi: 10.1016/j.ygyno.2009.09.005. Epub 2009 Oct 6.
6
Proteome profile of the MCF7 cancer cell line: a mass spectrometric evaluation.MCF7癌细胞系的蛋白质组图谱:质谱分析评估
Rapid Commun Mass Spectrom. 2006;20(20):3039-55. doi: 10.1002/rcm.2677.
7
Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer.综合分析卵巢癌细胞系的条件培养基,鉴定上皮性卵巢癌的新型候选标志物。
J Proteome Res. 2009 Oct;8(10):4705-13. doi: 10.1021/pr900411g.
8
The ovarian cancer-derived secretory/releasing proteome: A repertoire of tumor markers.卵巢癌来源的分泌/释放蛋白质组:肿瘤标志物的一个宝库。
Proteomics. 2012 Jun;12(11):1883-91. doi: 10.1002/pmic.201100654.
9
Proteins' promise--progress and challenges in ovarian cancer proteomics.蛋白质的前景——卵巢癌蛋白质组学的进展与挑战
Menopause Int. 2007 Dec;13(4):148-53. doi: 10.1258/175404507783004159.
10
Identification of biomarkers from mass spectrometry data using a "common" peak approach.使用“通用”峰方法从质谱数据中鉴定生物标志物。
BMC Bioinformatics. 2006 Jul 26;7:358. doi: 10.1186/1471-2105-7-358.

引用本文的文献

1
MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer.对来自囊液和血清的CA19-9进行MUC1和聚糖探测所捕获的生物标志物,可增强对卵巢癌的识别。
Sci Rep. 2025 Jan 25;15(1):3171. doi: 10.1038/s41598-025-86735-z.
2
Ovarian cancer ascites proteomic profile reflects metabolic changes during disease progression.卵巢癌腹水蛋白质组学图谱反映疾病进展过程中的代谢变化。
Biochem Biophys Rep. 2024 Jun 13;39:101755. doi: 10.1016/j.bbrep.2024.101755. eCollection 2024 Sep.
3
Mass spectrometry-based proteomics as an emerging tool in clinical laboratories.
基于质谱的蛋白质组学作为临床实验室中的一种新兴工具。
Clin Proteomics. 2023 Aug 26;20(1):32. doi: 10.1186/s12014-023-09424-x.
4
Mass Spectrometry-Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective.基于质谱的上皮性卵巢癌蛋白质组学:临床视角。
Mol Cell Proteomics. 2023 Jul;22(7):100578. doi: 10.1016/j.mcpro.2023.100578. Epub 2023 May 19.
5
Prognostic utility of the ovarian cancer secretome: a systematic investigation.卵巢癌分泌组的预后效用:系统研究。
Arch Gynecol Obstet. 2022 Sep;306(3):639-662. doi: 10.1007/s00404-021-06361-8. Epub 2022 Jan 27.
6
New Predictive Biomarkers for Ovarian Cancer.卵巢癌的新型预测生物标志物
Diagnostics (Basel). 2021 Mar 7;11(3):465. doi: 10.3390/diagnostics11030465.
7
Identification of core genes for early diagnosis and the EMT modulation of ovarian serous cancer by bioinformatics perspective.基于生物信息学视角鉴定卵巢浆液性癌早期诊断的核心基因和 EMT 调控作用。
Aging (Albany NY). 2021 Jan 25;13(2):3112-3145. doi: 10.18632/aging.202524.
8
In silico pathway analysis based on chromosomal instability in breast cancer patients.基于乳腺癌患者染色体不稳定性的计算机途径分析。
BMC Med Genomics. 2020 Nov 9;13(1):168. doi: 10.1186/s12920-020-00811-z.
9
Affinity-free enrichment and mass spectrometry analysis of the ovarian cancer biomarker CA125 (MUC16) from patient-derived ascites.无亲和力富集和质谱分析从患者来源的腹水的卵巢癌生物标志物 CA125(MUC16)。
Analyst. 2021 Jan 4;146(1):85-94. doi: 10.1039/d0an01701a.
10
Recent advances in mass spectrometry based clinical proteomics: applications to cancer research.基于质谱的临床蛋白质组学的最新进展:在癌症研究中的应用
Clin Proteomics. 2020 May 24;17:17. doi: 10.1186/s12014-020-09283-w. eCollection 2020.